Literature DB >> 16409161

Exercise-induced ventricular arrhythmias in patients with no structural cardiac disease.

Melvin M Scheinman1, Jason Lam.   

Abstract

We review the clinical and genetic disorders associated with exercise-induced ventricular arrhythmias in patients with normal hearts. Foremost are those with catecholaminergic polymorphic ventricular tachycardia due to abnormalities in either the ryanodine receptor 2 genes (RyR2) or the calsequestrin genes (CASQ). These patients manifest ventricular premature beats and polymorphic ventricular tachycardia in response to exercise or on exposure to catecholamines. A great deal of basic information has been accumulated suggesting that these arrhythmias are caused by abnormalities in Ca2+ metabolism. The ensuing cytosolic Ca2+ overload results in delayed after-depolarizations and extrasystolic Ca2+ waves, leading to polymorphic ventricular tachycardia. Most of these patients will respond to beta-blocker therapy but a significant minority (30%) will require a defibrillator. Advances in genetic testing allow better understanding of this syndrome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16409161     DOI: 10.1146/annurev.med.57.081704.090151

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  6 in total

1.  The catecholaminergic polymorphic ventricular tachycardia mutation R33Q disrupts the N-terminal structural motif that regulates reversible calsequestrin polymerization.

Authors:  Naresh C Bal; Ashoke Sharon; Subash C Gupta; Nivedita Jena; Sana Shaikh; Sandor Gyorke; Muthu Periasamy
Journal:  J Biol Chem       Date:  2010-03-30       Impact factor: 5.157

Review 2.  [Ventricular tachycardia. Diagnostic spectrum and therapeutic measures].

Authors:  T Lewalter; J O Schwab; G Nickenig
Journal:  Internist (Berl)       Date:  2006-10       Impact factor: 0.743

3.  Quantitative trait loci for exercise training responses in FVB/NJ and C57BL/6J mice.

Authors:  Michael P Massett; Ruzong Fan; Bradford C Berk
Journal:  Physiol Genomics       Date:  2009-09-29       Impact factor: 3.107

4.  The current status of iPS cells in cardiac research and their potential for tissue engineering and regenerative medicine.

Authors:  Ana M Martins; Gordana Vunjak-Novakovic; Rui L Reis
Journal:  Stem Cell Rev Rep       Date:  2014-04       Impact factor: 5.739

5.  Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia.

Authors:  Christian B Jung; Alessandra Moretti; Michael Mederos y Schnitzler; Laura Iop; Ursula Storch; Milena Bellin; Tatjana Dorn; Sandra Ruppenthal; Sarah Pfeiffer; Alexander Goedel; Ralf J Dirschinger; Melchior Seyfarth; Jason T Lam; Daniel Sinnecker; Thomas Gudermann; Peter Lipp; Karl-Ludwig Laugwitz
Journal:  EMBO Mol Med       Date:  2012-01-25       Impact factor: 12.137

Review 6.  Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Afford New Opportunities in Inherited Cardiovascular Disease Modeling.

Authors:  Daniel R Bayzigitov; Sergey P Medvedev; Elena V Dementyeva; Sevda A Bayramova; Evgeny A Pokushalov; Alexander M Karaskov; Suren M Zakian
Journal:  Cardiol Res Pract       Date:  2016-03-27       Impact factor: 1.866

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.